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Abstract
This is an overview of the cutaneous porphyrias. It is a narrative review based
on the published literature and my personal experience; it is not based on a
formal systematic search of the literature. The cutaneous porphyrias are a
diverse group of conditions due to inherited or acquired enzyme defects in the
porphyrin–haem biosynthetic pathway. All the cutaneous porphyrias can have
(either as a consequence of the porphyria or as part of the cause of the
porphyria) involvement of other organs as well as the skin. The single
commonest cutaneous porphyria in most parts of the world is acquired
porphyria cutanea tarda, which is usually due to chronic liver disease and liver
iron overload. The next most common cutaneous porphyria, erythropoietic
protoporphyria, is an inherited disorder in which the accumulation of
bile-excreted protoporphyrin can cause gallstones and, rarely, liver disease.
Some of the porphyrias that cause blistering (usually bullae) and fragility
(clinically and histologically identical to porphyria cutanea tarda) can also be
associated with acute neurovisceral porphyria attacks, particularly variegate
porphyria and hereditary coproporphyria. Management of porphyria cutanea
tarda mainly consists of visible-light photoprotection measures while awaiting
the effects of treating the underlying liver disease (if possible) and treatments to
reduce serum iron and porphyrin levels. In erythropoietic protoporphyria, the
underlying cause can be resolved only with a bone marrow transplant (which is
rarely justifiable in this condition), so management consists particularly of
visible-light photoprotection and, in some countries, narrowband ultraviolet B
phototherapy. Afamelanotide is a promising and newly available treatment for
erythropoietic protoporphyria and has been approved in Europe since 2014.
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An overview of the cutaneous porphyrias
The porphyrias affecting the skin can be divided into (1) those that 
present mainly with visible light–exposed site bullae and fragility 
(most commonly porphyria cutanea tarda [PCT]), (2) those, par-
ticularly erythropoietic protoporphyria (EPP), that present with 
neuropathic-type pain, oedema, erythema, and lesions on exposed 
sites (acute phototoxic porphyria), and (3) the extremely rare, 
severe, and mutilating porphyrias such as congenital erythropoietic 
porphyria (CEP; Günther’s disease). There are various classifica-
tion schemes, but if the porphyrias are considered from the point 
of view of the clinical cutaneous features, this is now one of many 
porphyria classification schemes1,2, along with considerations 
of where in the body overproduction of porphyrin intermediates 
occurs (hepatic or erythropoietic) and whether it is mainly a neu-
rovisceral attack porphyria or a cutaneous porphyria or where 
(which country) it was first described in detail (such as South 
African porphyria and Swedish porphyria).
For those not familiar with the cutaneous porphyrias, important 
general points are that (1) they are a diverse group of conditions, 
all showing skin diseases strictly limited to sun-exposed skin areas 
with a predilection for the backs of the hands and the face, and 
are due to a problem in the haem biosynthetic pathway—so certain 
types of cutaneous porphyria rather than ‘cutaneous porphyria’ 
should be part of a differential diagnosis list—(2) it is visible light 
(not ultraviolet) that is relevant, and (3) all the cutaneous porphyrias 
can also be associated with complicating diseases in organs other 
than the skin.
The porphyrias are a group of conditions caused by inherited or 
acquired enzyme defects in the haem biosynthesis metabolic 
pathway (Figure 1). All the porphyrias except acute intermittent 
porphyria and the exceptionally rare aminolevulinic acid (ALA) 
dehydratase deficiency porphyria (Doss porphyria) can affect the 
skin.
Two of the blistering (usually bullae, large blisters) and fragility 
(variegate porphyria [VP] and hereditary coproporphyria [HC]) 
porphyrias can also cause acute porphyria attacks. Acquired PCT 
is the one porphyria that is not primarily inherited but is a conse-
quence of chronic liver inflammation and liver iron overload. EPP 
can affect the biliary system and rarely the liver and is frequently 
associated with a mild anaemia.
The three commonest cutaneous porphyrias in the UK are PCT, 
which affects about 1 in 13,000 people in Scotland; EPP, which 
affects about 1 in 43,000 people in Scotland; and VP, which 
affects about 1 in 240,000 people in Scotland3. HC has skin mani-
festations identical to those of PCT and VP. The rare CEP and 
hepatoerythropoietic porphyria (homozygous inherited PCT) are 
usually severe but exceptionally rare (affecting less than one in 
a million3) diseases. Certain chemicals can induce a porphyria, 
such as hexachlorobenzene, a pesticide that caused an epidemic 
of a porphyria, with cutaneous features akin to PCT, in Turkey4. 
The term pseudoporphyria is usually used when porphyria is 
excluded as the cause of a PCT-like presentation, but the term is 
also used to encompass some features more similar to EPP, such as 
in children taking naproxen5, and is usually a drug-induced adverse 
effect (commonly caused by a non-steroidal anti-inflammatory drug 
and often naproxen), although it has also been reported with high 
cumulative exposure to sunbed radiation in the absence of a recog-
nised drug trigger. In kidney failure, a PCT-like presentation may 
not be due to an abnormality in porphyrin–haem metabolism or to a 
drug but to raised porphyrins due to failure to excrete them.
Diagnosis of the porphyrias is as with other conditions: it starts 
with history and examination. If a cutaneous porphyria like PCT is 
in the differential, a porphyrin plasma scan (plasma spectrofluor-
imetry) and quantitative urine porphyrins are appropriate initial 
tests6. If these are positive, then fluorescent high-performance 
liquid chromatography on urine and stool porphyrins are appropri-
ate in order to differentiate among PCT, VP, and HC. If acquired 
PCT is strongly suspected, it is appropriate to start investigating 
for underlying causes, including iron accumulation, chronic 
hepatitis B or C, or HIV, even while still investigating to determine 
whether the patient does have PCT. If EPP is considered, then 
it is appropriate to request a porphyrin plasma scan and quantitative 
erythrocyte protoporphyrin.
Acute phototoxic symptoms
Erythropoietic protoporphyria
EPP, which is due to reduced ferrochelatase activity (Figure 1), is 
the second most common cutaneous porphyria, affecting about 2.3 
per 100,000 population in the Dundee area3. This estimate is higher 
than a survey of diagnosed UK cases suggested (0.86 per 100,000); 
similar discrepancies were seen in prevalence estimates for the 
whole of Denmark compared with a region in Denmark, including 
a centre with a particular interest in this condition7.
EPP is the most frequent porphyria to present in childhood. Its 
clinical features are very different from those of the cutane-
ous porphyrias that present mainly with blistering and fragility. 
Rarely, a form of EPP can occur as an acquired problem, usually 
associated with myelodysplastic conditions such as sideroblastic 
anaemia8. Recently, a condition that used to be grouped together 
with EPP, X-linked protoporphyria, has been distinguished (see 
below). Within the differential, there are sometimes certain pat-
terns of drug-induced phototoxicity and atypical polymorphic light 
eruption. Also in the differential, when EPP induces urticaria, it 
is usually idiopathic solar urticaria. In fact, EPP was originally 
classified as type VI solar urticaria9,10.
The main feature is pain, of a burning or prickling quality, in skin 
exposed to as little as a few minutes of sunlight (which might be 
cloud or window glass–transmitted, as it is visible radiation that is 
predominantly responsible for the exposed site skin symptoms in 
this, as in the other, porphyrias). Typically, the pain is severe, and 
those affected withdraw from further exposure if possible and often 
try to obtain some relief by various manoeuvres, often running cold 
water or applying cold packs on skin or sometimes using a cream 
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containing menthol or similar over-the-counter counter-irritant 
topical preparations such as ‘Tiger Balm’ (Haw Par Corporation, 
Singapore).
Only if further exposure is unavoidable will swelling appear as a 
result of endothelial damage, leading to increased dermal tissue 
fluid. Sometimes redness appears and purpura can occur if there 
is sufficient damage to the endothelium that red blood cells as 
well as dermal tissue fluids leak into the dermis. With repeated 
exposures of this kind, there can be a typical linear (but rather 
chicken pox-like) scarring and a waxy thickening of skin, 
especially over the dorsal nose and knuckles. Other features, such 
as rhagades, can develop11. Palmar keratoderma is especially 
associated with classic autosomal recessive inheritance12.
This condition typically presents first in childhood, with the parents 
noticing that a baby cries when exposed to sunlight. Because of the 
frequent absence of physical signs, there is often a very prolonged 
delay in diagnosis; in a survey of most of the UK EPP patients, a 
delay of a median of 12 years before diagnosis was reported11. In 
countries with compulsory national service, EPP is one of those 
conditions that can initially be mistaken for malingering.
Figure 1. Simplified porphyria–haem biosynthetic pathway illustrating the enzyme defects (decreased activity for all except 
aminolevulinic acid (ALA) synthase 2 with which increased activity causes X-linked protoporphyria) involved in the main 
porphyrias.
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Inheritance is now recognised in about 9 out of 10 people 
with EPP to be ‘autosomal co-dominant’ (a form of autosomal 
recessive) where a major sporadic mutation in the gene encoding 
ferrochelatase is inherited from one parent and a polymorphism is 
inherited from the other parent. A common polymorphism that 
leads to slightly reduced ferrochelatase activity is frequent and 
found in almost 11% of a western European population and at 
higher frequency in a Japanese population, mainly accounting for 
the worldwide distribution of the prevalence of EPP13,14.
Apart from the skin features, gallstones are common and can become 
troublesome. A mild anaemia, often of a hypochromic microcytic 
pattern, is frequent15,16. The main relevance of this is that if this 
anaemia is treated with iron, this can be counterproductive. Low 
iron stores appear to be protective in erythropoietic porphyrias17.
EPP liver failure is not common: two cases were found in a study 
of almost 400 UK patients11, and I know of one patient in Scotland 
who died of protoporphyria liver failure within the past 25 years. 
This is an important complication to be aware of, however, as it 
can start seemingly rather innocuously with only a moderate rise 
in transaminases that in other situations (such as suspected 
alcoholic liver disease) would not generally cause much concern 
but in EPP should prompt early action. The review by Anstey and 
Hift in the Postgraduate Medical Journal18 and Gut19 is helpful.
The diagnosis can be made on the basis of symptoms, an abnormal 
plasma scan (peak emission at 630 to 635 nm), and elevated red 
blood cell (erythrocyte) protoporphyrin. On a whole blood scan, 
most of the excess protoporphyrin is unchelated. At diagnosis, it is 
usual to check full blood count and liver function tests (LFTs). It 
is advisable to monitor with LFTs, although there is no consensus 
on what tests should be done or how frequently18,19. I usually rec-
ommend 6-monthly LFTs and erythrocyte protoporphyrins in an 
attempt to pick up early any evidence of liver failure developing 
or marked increase in porphyrin that might be associated with an 
increased risk of subsequent liver failure.
Management involves telling the patient the diagnosis, genetic 
counselling as appropriate to the individual’s situation, and advice 
on environmental, behavioural, clothing, and topical sunscreen pho-
toprotection. It is important to explain to patients that it is visible 
light that causes the skin symptoms and to tailor advice to reducing 
visible-light exposure. This may be obvious to patients, but in 
Scotland many initially think that it must be ultraviolet—because 
almost everyone is familiar with normal sunburn, caused mainly 
by ultraviolet B (UVB)—that is relevant, and a lot is more under-
standable to them once they understand that this is a visible-light 
problem. ‘Daylight’, at least in Scotland, is a term that can help 
people understand the distinction from the ultraviolet in sunlight 
that causes sunburn. For example, most commercially available 
sunscreens are minimally effective in visible-wavelength prob-
lems, including the cutaneous porphyrias. In fact, most commercial 
sunscreens that contain reflective particles such as titanium diox-
ide deliberately use small particle sizes to improve their efficacy 
in ultraviolet protection and reduce their reflection of visible light 
(as such reflection of wavelengths that the human eye can see 
unavoidably makes a sunscreen messier). However, a 
large-particle-size titanium dioxide sunscreen (such as that made by 
the UK National Health Service orphan drug manufacturer Tayside 
Pharmaceuticals) can be of benefit for visible-light photoprotection 
if used along with other measures20.
All medical interventions for the prevention of the cutaneous 
phototoxicity of EPP, with the exception of afamelanotide (see 
below), have been poorly studied21. Beta-carotene has often been 
tried, but its true efficacy is uncertain, as complete blinding in 
studies is impossible because of the skin colour changes produced 
at doses that might work22–25.
The study by Corbett et al. was a randomised crossover study with 
blinding maintained when possible. I performed some analyses 
myself on their published data, as confidence intervals were not 
presented and P values were just given as <0.05 or not without more 
detail24. Fourteen people with EPP were recruited and 11 com-
pleted the crossover study (random order of allocation to placebo or 
beta-carotene): the authors reported no detectable difference in 
one main outcome measure (‘hours out of doors’) and reported 
being unsure of the accuracy of patient recording of the other main 
outcome measure recorded (on diary cards), ‘hours outdoors 
in bright sunlight’. Patients reported a mean of 23.1 ‘hours 
outdoors in bright sunlight’ over 5 weeks on beta-carotene com-
pared with a mean of 15.7 hours over 5 weeks on placebo; that is, on 
beta-carotene, a mean of 7.4 (95% confidence interval 1.1 to 
13.7) more hours were recorded ‘outdoors in bright sunlight’ 
(P = 0.026). The authors considered that although this difference 
was statistically significant (unlikely due to chance), it was likely 
to be ‘clinically insignificant’. Other antioxidants have been tried, 
but controlled crossover studies (such as that by Bijlmer-Iest 
et al.26) did not detect benefit with N-acetylcysteine, and although 
another small study showed possible benefit with vitamin C, this 
drug has not continued to be used routinely in the centre that 
performed the study27. H1 antihistamines can reduce the weal-flare 
response in solar urticaria occurring as a manifestation of EPP28.
Narrowband UVB phototherapy can provide useful protection 
presumed in part to be through inducing epidermal thickening 
and also possibly through increased pigmentation (tanning)29–31, 
although it is unlikely that this is a major way in which it works. 
A personal clinical observation from working in an area where 
many are of sun-reactive skin phototype I (and so do not tan with 
sunlight or UVB phototherapy) is that there does not seem to be 
any connection between tanning and a good response to treatment. 
Narrowband UVB lamps (TL-01 lamps, Philips, Eindhoven, The 
Netherlands) emit some visible light along with the UVB, but 
in practice there is proportionately so little visible light that this 
treatment does not cause EPP phototoxicity. In a review of 80 
courses of UVB given to 12 patients (of whom seven reported 
a ‘good benefit’), only two experienced EPP symptoms due 
to daylight exposure, not due to treatment, while attending for 
narrowband UVB phototherapy30. In that case series, two had 
episodes of well-demarcated erythema after UVB; this was 
sunburn-like UVB erythema, not EPP phototoxicity. Anecdotally, 
when EPP patients experience normal mild sunburn during a course 
of UVB, they are often pleased, having never experienced normal 
sunburn before (because the EPP phototoxicity has previously 
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prevented sufficient sunlight exposure to allow doses of normally 
erythemogenic wavelengths to cause this). Possibly, part of the 
way narrowband UVB works is through the same main mecha-
nism that is thought to explain its efficacy in chronic urticaria, that 
of mast cell stabilisation32. There is some in vitro evidence that 
after porphyrin absorbs visible light, later degranulation of mast 
cells is an important part of the process33,34. There are many other 
effects, beyond simple physical ‘hardening’, of UVB which could 
contribute to its effectiveness.
Afamelanotide, an alpha-melanocyte stimulating hormone 
(α-MSH) analogue, improves skin photosensitivity in EPP35. It 
increases eumelanin production, which may be of benefit par-
tially through direct photoprotection effects and also through the 
effects of eumelanin as a free radical scavenger. Moreover, α-MSH 
modulates skin inflammation and increases antioxidant enzymes. It 
causes tanning, making blinded study difficult. Its very long-term 
safety is not yet known, although a study with up to 8 years of 
experience has been published36. In a multicentre randomised 
European study, those on afamelanotide reported a median of 6 
(range of 0 to 193) hours daily outside in direct sunlight over the 
9 months of the study without pain compared with 0.8 (range of 0 
to 35) hours (P = 0.005) amongst those allocated placebo, and in 
a USA study, those allocated afamelanotide reported a median of 
69.4 (range of 0 to 651) hours out in direct sunlight without pain 
over 6 months of study compared with a median of 40.8 (range 
of 0 to 224) hours (P = 0.04) amongst those allocated placebo37. 
There are reports of 93% of treated EPP patients having a marked 
response, and those on it tend to stay on it36, so this may turn out 
to be a highly useful treatment. Also, study is difficult, particularly 
because people with EPP become frightened of sunlight exposure, 
so in the randomised studies (Europe and the USA) patients may 
still have gone out less than they would have been able to for fear 
of painful reactions, so this study endpoint might not have fully 
reflected the benefits of afamelanotide. Conversely, perhaps many 
of those who received afamelanotide guessed they were on active 
treatment because of tanning and so went out longer (so possibly 
gaining benefit through greater exposure to sunlight38).
This drug is now licensed (and has marketing authorisation for the 
prevention of phototoxicity in adult EPP patients) in Europe. It is 
already in use in some countries and in others is currently being 
considered by bodies such as the Scottish Medicines Consortium. 
Ideally, I think, there should now be a study directly comparing it 
with another intervention such as narrowband UVB (perhaps given 
as home phototherapy). Langendonk et al. have shown that large 
multicentre studies in such a rare condition can be done37. Others 
think that first a study on the effectiveness and safety of UVB using 
a double-blind design should be performed.
Cimetidine has been tried and reported to be helpful for some39–41, 
although these cases were not clearly reported42. If it really works, 
it is more plausible that it is working as an H2 antihistamine in the 
skin, as in solar urticaria43, rather than working through inhibiting 
ALA synthase. It is hepatic ALA synthase 1, not erythroid ALA 
synthase 2, that it inhibits.
Various measures to increase protoporphyrin elimination in 
bile—such as colestyramine (cholestyramine) and activated 
charcoal—have been tried for incipient liver failure17,18,44,45. 
Colestyramine does not appear to have an effect on red cell 
porphyrins in EPP46. Liver transplantation has saved the lives of 
patients with liver failure47, although EPP symptoms continue 
after such a transplant and, as the recurrence rate of liver disease 
is high, bone marrow transplantation has been conducted at the 
same time as liver transplantation to prevent future failure of the 
transplant due to protoporphyria liver disease47,48. If a patient with 
EPP does need surgery, particularly for liver transplantation that 
is being conducted because of EPP liver failure (when porphyrin 
levels are typically especially high), operating theatre lamps should 
be shielded to particularly reduce violet and blue wavelengths 
of visible light49.
X-linked protoporphyria
This has recently been described as a distinct disease50. In the 
past, most patients with this condition were probably considered 
to have classic EPP. In this condition, in contrast to EPP, there is 
not a reduced activity of the ferrochelatase enzyme but instead 
an increased activity of the ALA synthase 2 enzyme, which is 
expressed only in the red blood cell line (Figure 1). So, in this con-
dition, problems caused by increased protoporphyrin are caused by 
total increased protoporphyrin production rather than insufficient 
enzyme activity to chelate iron into protoporphyrin. This is rele-
vant regarding diagnosis. In classic EPP, there is a marked increase 
in free protoporphyrin, whereas in X-linked EPP there is also an 
increase in zinc chelated protoporphyrin; this is because the fer-
rochelatase enzyme is of normal activity and able to chelate some 
of the excess protoporphyrin with divalent metals such as zinc. 
Possibly in this condition, unlike in classic EPP, iron supplementa-
tion may turn out to be a useful treatment51.
Bullae and skin fragility
Porphyria cutanea tarda
This is the commonest of the cutaneous porphyrias in Europe and 
probably worldwide. The prevalence in Dundee is 1 in 13,0003. 
PCT is important not only in its own right but also because sporadic 
PCT (sometimes called type 1 PCT) is a marker for liver disease 
and an increased risk of hepatocellular carcinoma. PCT is caused 
by a reduction in the activity of uroporphyrinogen decarboxylase 
(Figure 1), and different inherited patterns of this deficiency give 
rise to the rare types (2 and 3). Most cases of PCT are type 1, which 
is also known as ‘sporadic’ or ‘acquired’. In these patients, liver 
disease and iron overload are necessary to reduce this enzyme activ-
ity level sufficiently for PCT to develop.
When chronic hepatitis induces PCT, liver iron overload is usu-
ally present, and heterozygosity for a haemochromatosis gene 
contributes to PCT development in many affected individuals52,53. 
In Europe, the most common causes of PCT are excessive alcohol 
consumption, chronic hepatitis C infection, other liver-related 
chronic viral infections (including HIV), autoimmune chronic 
hepatitis (for example in systemic lupus erythematous), and 
haemochromatosis. Medications are not triggers in contrast to the 
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acute porphyrias (see below), except for oestrogens that may play a 
part in inducing PCT in some people54, and treatment with iron will 
exacerbate PCT.
Sporadic PCT usually first develops over the age of 40 and seems 
to be more common in men than in women. The most frequent 
presentation is with blisters, skin fragility, and delayed healing 
of wounds on the maximally photo-exposed sites of dorsal hands. 
Upon healing, the subepidermal blisters of PCT typically result in 
milia; classically, these are seen on the maximally photo-exposed 
sites of the dorsal hands. In most PCT patients, this means most 
frequent localisation over dorsal thenar eminences, proximal index 
and middle fingers, and thumbs. Different distributions can be seen 
dependent upon the patient’s occupation; for example, I recently 
saw a taxi driver with more involvement of distal dorsal fingers and 
with finger nail changes, including onycholysis. Hypertrichosis 
also frequently appears; it often first manifests on the temples but 
can appear in areas that are not photo-exposed. Another frequent 
feature is pigmentation, particularly of areas that are photo-exposed, 
and is sometimes the only presenting sign. Solar urticaria is rarely 
seen on presentation55,56, although urticarial responses can be found 
on monochromator phototesting57.
Scleroderma-like changes are infrequent in PCT but have been 
thoroughly reported58. Many PCT sufferers are not initially aware 
of the involvement of sunlight. This is because (1) it is visible (not 
ultraviolet) wavelength radiation that leads to the changes in the 
skin, so seasonal variation is not always apparent, and (2) it is 
mainly chronic, and not discrete episodes of, sunlight exposure that 
result in symptoms.
When one is evaluating a patient exhibiting typical features, the 
primary differential diagnoses to consider are VP, HC, and drug-
induced pseudoporphyria. A peak at around 620 nm on plasma 
spectrofluorimetry is present in both PCT and HC. The diagnosis 
of PCT can be corroborated by quantification of urine and stool 
porphyrins. PCT patients excrete increased amounts of isocopro-
porphyrin in faeces, whereas both VP and HC patients show a 
strongly increased coproporphyrin III isomer. Urinary porphyrin 
concentrations can be used to monitor the response to therapy. In an 
unusually young patient (younger than 30 years old) presenting 
with PCT, the mainly inherited PCT types should be taken into 
account. In most cases, sporadic PCT is the diagnosis, and sub-
sequently the underlying liver insults and whether or not there is 
clear evidence of iron overload must be determined. All patients 
are investigated for transaminases, hepatitis B and C serology, fer-
ritin, and alfa-fetoprotein (because of the risk of hepatocellular 
carcinoma).
A liver ultrasound is often done (particularly to look for hepato-
cellular carcinoma) but liver biopsy is rarely indicated. In areas 
where there is a high prevalence of HIV, patients should always 
undergo HIV serologic testing. In areas where there is a low prev-
alence, the occurrence of HIV testing is expected to be low, but 
investigation must still take place if there are other pointers to this 
diagnosis (such as mouth ulcers, chronic diarrhoea, weight loss, or 
behavioural risk factors) or, regardless of the presence or absence 
of behavioural/lifestyle risk factors, if the PCT presentation is 
unusual (for example, in a young woman who drinks little alcohol) 
and initial investigations have been unrewarding.
Management involves eliminating the causes of underlying liver 
disease and iron overload when possible. Patients should be advised 
to avoid alcohol (irrespective of whether or not it is thought to be 
the cause of the primary liver insult), medications containing iron 
must be stopped, and oestrogens should be stopped or changed to 
low systemic dose transdermal preparations. When possible, viral 
hepatitis should be treated, and several PCT patients I have been 
following up over the past two decades have been cured by some 
of the newer anti–hepatitis C drugs. The likelihood of hepatitis 
C treatment being effective is possibly increased if iron overload 
is addressed first59. Iron overload is usually treated by venesec-
tion. Iron chelation therapy (with desferrioxamine or one of the 
newer oral iron chelators) is an alternative approach that can be 
useful when iron overload is associated with anaemia (such as in a 
haemodialysis patient with PCT60).
Another approach, which can be combined with venesection, is 
to treat with low-dose chloroquine or hydroxychloroquine. These 
drugs are thought to work by increasing porphyrin excretion. Chlo-
roquine rather than hydroxychloroquine is usually used, as there is 
more experience in using this in PCT and the doses used (such as 
250 mg chloroquine phosphate weekly) are low enough that ocular 
toxicity is not an important concern61. Owing to the risks of severe 
hepatotoxicity, higher doses should not be used. While patients 
await the effects of these treatments, adopting sunlight avoidance 
measures is important. Visible-light exposure can be lowered by 
behavioural avoidance, wearing suitable clothing (for example, 
dark-coloured driving gloves), and applying a large-particle-size 
titanium dioxide sunblock. Also, protecting the hands from trauma 
during manual work and leisure activities (such as gardening) 
by wearing gloves is beneficial. For male patients, the use of an 
emulsifying ointment as an alternative to shaving foam, applied for 
10 minutes before shaving, can help reduce facial shaving trauma.
Acute porphyrias with skin manifestations (variegate and 
hereditary coproporphyria)
Cutaneous features of VP and HC can be identical to those of PCT. 
Features of an acute attack include gastrointestinal symptoms 
(abdominal pain, nausea, vomiting, constipation, and diarrhoea), 
neurological symptoms (motor and sensory peripheral neu-
ropathies, muscle pain, ascending paralysis, anxiety, psychosis, 
coma, seizures, and respiratory paralysis requiring ventilation), 
cardiovascular symptoms (tachycardia and hypertension), and 
renal failure62.
The Norway-based NAPOS (http://www.drugs-porphyria.org) 
porphyria website can provide useful guidance when prescribing 
drugs to people with acute attack porphyrias and when consider-
ing possible triggers for an acute attack. Those affected who have 
had multiple attacks will often have learnt which drugs alleviate 
their symptoms and are safe for them. Such patients presenting to a 
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hospital where they are not known, and requesting a high dose of a 
particular opiate and an anti-emetic such as chlorpromazine, may 
initially be suspected of being drug addicts.
Screening of family members of VP- and HC-index patients should 
be undertaken. In VP, a negative plasma fluorescence test is still 
associated with a 1-in-8 risk for a first-degree relative over 15 years 
of age; a second-degree relative has only a 1-in-22 risk (close to the 
certainty achieved by measuring protoporphyrin oxidase enzyme 
activity)63. Previously, genetic testing was difficult, except in those 
from the Western Cape in South Africa, where one particular muta-
tion accounts for the majority of cases64, but genetic testing is now 
more generally useful65 and is the standard approach for screening 
of family members.
Management of the cutaneous aspects of these porphyrias involves 
the same advice on reducing visible-light exposure as for the other 
porphyrias. Acute attacks are managed as for acute intermittent 
porphyria. That is, efforts must be taken to avoid inducing attacks 
(such as by prescribing porphyrinogenic drugs) and to prevent 
attacks being set off by known triggers (such as dieting). Oral 
tin-protoporphyrin may (by negative feedback reducing ALA 
synthase activity) help prevent acute attacks66,67 but is itself a toxic 
photosensitiser that can cause symptoms akin to those of EPP 
and so is not used now. Through a direct inhibition of the haem 
biosynthetic pathway (particularly reduced ALA synthase activity), 
carbohydrate loading can also be useful in less severe attacks or as 
an attack preventative measure. Intravenous haem arginate (a haem 
analogue) aborts acute attacks and should be considered for acute 
attacks, including for those who have had previous life-threatening 
attacks. In some countries, such as in England and Wales (Scotland 
will be joining), there is an acute porphyria service which can help 
in advising whether haem arginate should be used and getting it 
supplied if recommended.
Severe scarring porphyrias
Congenital erythropoietic porphyria (Günther’s disease)
CEP is very rare, affecting less than 1 in a million in Scotland3,68. 
Severe photosensitivity occurs with phototoxicity, blistering, chronic 
ulcers, and delayed healing and mutilation of light-exposed parts. 
Hypersplenism, haemolytic anaemia with thrombocytopaenia, 
may occur. Erythrodontia, brown teeth that fluoresce under Wood’s 
lamp (a violet lamp with peak irradiance at about 410 nm) 
illumination, is another sign. Milder variants with onset in 
adult life can occur and have presented with and without 
thrombocytopaenia69,70. Management of severely affected individu-
als means strict attempts to avoid visible solar radiation reaching 
the skin and eyes. Bone marrow transplantation is used for the 
most severe cases. Katugampola et al. have suggested a plan for the 
multidisciplinary management of people with CEP and criteria to 
consider when determining whether bone marrow transplantation 
is appropriate71.
Homozygous and mixed porphyrias
These tend to present early, and features include scarring 
(frequently causing scarring alopecia and syndactyly) in many 
patients. Hepatoerythropoietic porphyria (homozygous inherited 
PCT) can present with the clinical features of CEP but the bio-
chemistry of PCT. Homozygous VP is now well characterised72, 
presenting in childhood, with short stature, and photosensitivity 
with features suggesting very severe PCT, including scarring and 
clinodactyly. Homozygous VP has not been associated with acute 
neurovisceral attacks.
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